Filing Flows › Harvard Apparatus Regenerative Technology (HRGN) › Q2 2026
Harvard Apparatus Regenerative Technology (HRGN) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Harvard Apparatus Regenerative Technology (HRGN) reported revenue of $414K for the second quarter 2026 (Q2 2026), +31% from a year earlier and +83% from the quarter before. Operating margin was -408.7%, net loss $1.7M (409.4% of revenue).
Harvard Apparatus Regenerative Technology, Q2 2026: revenue $414K (+31% year over year), operating margin -408.7%, net loss $1.7M, operating cash flow −$569K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $414K | +83% | +31% |
| Operating profit | −$1.7M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$569K | — | — |
What changed
Revenue was $414K in Q2 2026, up 31% year over year and up 83% from the previous quarter.
Operating costs exceeded revenue by $1.7M, an operating margin of -408.7%. Total costs fell 2% while revenue rose 31%. The fastest-growing cost line was Research & development (+36%). The quarter ended with a net loss of $1.7M, wider than the previous quarter's $1.6M loss.
Operating cash flow was −$569K. Non-cash charges added back $1K of depreciation and $223K of share-based compensation. Working capital and other items added $902K.
Questions
What was Harvard Apparatus Regenerative Technology's revenue in the second quarter 2026?
Harvard Apparatus Regenerative Technology (HRGN) reported revenue of $414K for the second quarter 2026 (Q2 2026), +31% from a year earlier and +83% from the quarter before.
Was Harvard Apparatus Regenerative Technology profitable in the second quarter 2026?
Operating loss was $1.7M (-408.7% of revenue) and net loss $1.7M.
Source: Harvard Apparatus Regenerative Technology 10-Q on SEC EDGAR.